|
|
News Breaks
|
February 9, 2010
|
| 10:05 EDT |  | RNN |
| theflyonthewall.com: | BioMedReports says Rexahn Pharma is undervalued | | BioMedReports says Rexahn currently has three drug candidates in Phase II clinical trials, Archexin, Serdaxin, and Zoraxel - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. BioMedReports' staff is calling this the most undervalued biotech they have seen in a long time and since they are presenting today at the 12th Annual BIO CEO & Investor Conference at The Waldorf Astoria, New York City. We have a feeling they won't be undiscovered for much longer. Reference Link :theflyonthewall.com |
|
|
News For RNN From The Last 14 Days Check below for free stories on RNN the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
